Patents Assigned to Neuraltus Pharmaceuticals, Inc.
  • Chlorite formulations, and methods of preparation and use thereof
    Patent number: 9839650
    Abstract: Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: December 12, 2017
    Assignee: NEURALTUS PHARMACEUTICALS, INC.
    Inventors: William Boulanger, Arasteh Ari Azhir
  • Treatment of macrophage-related disorders
    Patent number: 9579346
    Abstract: The present invention provides a method of treating a macrophage related disease comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The present invention also provides a method of modulating macrophage accumulation or activation comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The oxidative agent can be chlorite or a chlorite containing compound.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: February 28, 2017
    Assignees: The Regents of the Univerity of California, Neuraltus Pharmaceuticals, Inc.
    Inventors: Michael S. McGrath, Arasteh Ari Azhir
  • Chlorite formulations and methods of preparation and use thereof
    Patent number: 9266734
    Abstract: Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.
    Type: Grant
    Filed: September 29, 2011
    Date of Patent: February 23, 2016
    Assignee: NEURALTUS PHARMACEUTICALS, INC.
    Inventors: William Boulanger, Arasteh Ari Azhir
  • Compositions and methods for treating lysosomal disorders
    Patent number: 9023845
    Abstract: The present invention provides compositions and methods for treating lysosomal disorders using a class of substituted imidazole derivatives or compounds.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: May 5, 2015
    Assignees: Neuraltus Pharmaceuticals, Inc., The Hospital for Sick Children
    Inventors: Clifford A. Lingwood, Michael S. McGrath, Arasteh Ari Azhir
  • TREATMENT OF MACROPHAGE-RELATED DISORDERS
    Publication number: 20150037320
    Abstract: The present invention provides a method of treating a macrophage related disease comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The present invention also provides a method of modulating macrophage accumulation or activation comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The oxidative agent can be chlorite or a chlorite containing compound.
    Type: Application
    Filed: May 6, 2014
    Publication date: February 5, 2015
    Applicants: Neuraltus Pharmaceuticals, Inc., The Regents of the University of California
    Inventors: Michael S. McGrath, Arasteh Ari Azhir
  • Chlorite formulations and methods of preparation and use thereof
    Patent number: 8501244
    Abstract: Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.
    Type: Grant
    Filed: September 29, 2011
    Date of Patent: August 6, 2013
    Assignee: Neuraltus Pharmaceuticals, Inc.
    Inventors: William Boulanger, Arasteh Ari Azhir
  • Compositions and Methods for Treating Lysosomal Disorders
    Publication number: 20130012539
    Abstract: The present invention provides compositions and methods for treating lysosomal disorders using a class of substituted imidazole derivatives or compounds.
    Type: Application
    Filed: July 17, 2012
    Publication date: January 10, 2013
    Applicants: The Hospital for Sick Children, Neuraltus Pharmaceuticals, Inc.
    Inventors: Clifford A. Lingwood, Michael S. McGrath, Arasteh Ari Azhir
  • Compositions and methods for treating lysosomal disorders
    Patent number: 8252789
    Abstract: The present invention provides compositions and methods for treating lysosomal disorders using a class of substituted imidazole derivatives or compounds.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: August 28, 2012
    Assignee: Neuraltus Pharmaceuticals, Inc.
    Inventors: Clifford A. Lingwood, Michael S. McGrath, Arasteh Ari Azhir
  • Chlorite formulations and methods of preparation and use thereof
    Patent number: 8231856
    Abstract: Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.
    Type: Grant
    Filed: May 9, 2011
    Date of Patent: July 31, 2012
    Assignee: Neuraltus Pharmaceuticals, Inc.
    Inventors: William Boulanger, Arasteh Ari Azhir
  • Chlorite Formulations and Methods of Preparation and Use Thereof
    Publication number: 20120021069
    Abstract: Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.
    Type: Application
    Filed: September 29, 2011
    Publication date: January 26, 2012
    Applicant: Neuraltus Pharmaceuticals, Inc.
    Inventors: William Boulanger, Arasteh Ari Azhir
  • Chlorite Formulations and Methods of Preparation and Use Thereof
    Publication number: 20120021070
    Abstract: Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.
    Type: Application
    Filed: September 29, 2011
    Publication date: January 26, 2012
    Applicant: Neuraltus Pharmaceuticals, Inc.
    Inventors: William Boulanger, Arasteh Ari Azhir
  • Chlorite Formulations and Methods of Preparation and Use Thereof
    Publication number: 20120015051
    Abstract: Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.
    Type: Application
    Filed: May 9, 2011
    Publication date: January 19, 2012
    Applicant: Neuraltus Pharmaceuticals, Inc.
    Inventors: William Boulanger, Arasteh Ari Azhir
  • Chlorite formulations, and methods of preparation and use thereof
    Patent number: 8067035
    Abstract: Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: November 29, 2011
    Assignee: Neuraltus Pharmaceuticals, Inc.
    Inventors: William Boulanger, Arasteh Ari Azhir